The Phase 3 PIVOT-PO trial met its primary endpoint, demonstrating non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTIs.
The Independent Data Monitoring Committee (IDMC) recommended stopping the trial early due to the compelling efficacy results observed in the interim analysis.
Tebipenem HBr has the potential to be the first oral carbapenem antibiotic for cUTIs in the US, addressing a critical unmet need for an oral alternative to intravenous treatments.
Approximately 2.9 million cases of cUTIs are treated annually in the US, contributing to over $6 billion in healthcare costs. Tebipenem HBr could reduce these costs by minimizing hospitalizations.
GSK plans to submit the PIVOT-PO trial data as part of a planned US Food and Drug Administration (FDA) filing in the second half of 2025.
Why does this matter?
The successful trial results and potential FDA approval of tebipenem HBr could revolutionize the treatment landscape for cUTIs. An oral treatment option can significantly improve patient convenience, reduce healthcare costs, and minimize the need for hospitalizations associated with intravenous antibiotics.
Complicated urinary tract infections (cUTIs) pose a significant healthcare burden, often requiring hospitalization and intravenous antibiotic treatment. The current standard of care includes carbapenem antibiotics, which are highly effective but only available for IV administration. Spero Therapeutics and GSK's development of tebipenem HBr aims to address this limitation by providing an oral carbapenem option.
The PIVOT-PO trial was a global, randomized, double-blind study that enrolled 1,690 patients with cUTIs, including pyelonephritis. Patients were randomized to receive either oral tebipenem HBr or intravenous imipenem-cilastatin. The primary efficacy endpoint was the overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.
The trial met its primary endpoint, demonstrating that tebipenem HBr was non-inferior to intravenous imipenem-cilastatin. The IDMC's recommendation to stop the trial early further underscores the strength of the efficacy data. The safety profile of tebipenem HBr was consistent with previous studies, with diarrhea and headache being the most commonly reported adverse events.
The development of tebipenem HBr is supported by federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA). This funding highlights the importance of developing new treatments for multi-drug resistant bacterial infections.
Actionable takeaways:
Patients with cUTIs may soon have access to an oral carbapenem antibiotic, reducing the need for hospitalization and IV treatments.
Healthcare providers should stay informed about the potential approval and availability of tebipenem HBr to optimize treatment strategies for cUTIs.
The successful development of tebipenem HBr demonstrates the importance of investing in research and development of new antibiotics to combat multi-drug resistant infections.
Q: What were the results of the Phase 3 PIVOT-PO trial for tebipenem HBr?
The trial met its primary endpoint early, demonstrating non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in treating complicated urinary tract infections (cUTIs).
Q: When will Spero Therapeutics submit tebipenem HBr for FDA approval?
GSK plans to submit the FDA filing in the second half of 2025, which will include the PIVOT-PO trial data.
Q: What is the market potential for tebipenem HBr?
The drug addresses an estimated 2.9 million annual cUTI cases in the US, with current treatments contributing to over $6 billion in yearly healthcare costs.
Q: What are the main side effects of tebipenem HBr?
The most commonly reported adverse events in the trial were diarrhea and headache.
Q: How is tebipenem HBr different from existing cUTI treatments?
If approved, tebipenem HBr would be the first oral carbapenem antibiotic for US patients with cUTIs, potentially reducing the need for hospital-based intravenous treatment.
Spero Therapeutics and GSK's tebipenem HBr shows promise as the first oral carbapenem antibiotic for complicated UTIs in the US.
The Phase 3 PIVOT-PO trial met its primary endpoint, leading to early termination due to efficacy.
If approved, tebipenem HBr could reduce hospitalizations and healthcare costs associated with cUTI treatment.
GSK plans to submit the data for FDA approval in the second half of 2025.
The most common side effects observed in the trial were diarrhea and headache.
Do you think this new oral treatment will significantly impact the management of complicated UTIs? Share this article with others who need to stay ahead of this trend!
Intellia Therapeutics (NASDAQ:NTLA) has temporarily paused patient dosing and screening in its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical tr...
Lyra Therapeutics (LYRA) has announced positive results from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a long-acting sinonasal imp...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer